Nuclear factor kappa B: Important transcription factor and therapeutic target

Journal of Clinical Pharmacology

Volumn 38, Issue 11, 1998, Pages 981-993

  Lee, Jang Ik ^a   Burckart, Gilbert J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ACETYLSALICYLIC ACID; ANTIOXIDANT; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SALICYLIC ACID DERIVATIVE; TACROLIMUS; TEPOXALIN; TRANSCRIPTION FACTOR;

ASTHMA; GENETIC TRANSCRIPTION; GRAFT REJECTION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; PROTEIN ANALYSIS; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0031757934     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009803801101     Document Type: Review

References (81)

1. Sen R, Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705-716.
2. Thanos D, Maniatis T: NF-κB: a lesson in family values. Cell 1995;80:529-532.
3. Blackwell TS, Christman JW: The role of nuclear factor-IκB in cytokine gene regulation. Am J Respir Cell Mol Biol 1997;17:3-9.
4. Baldwin AS: The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-681.
5. Wulczyn FG, Krappmann D, Scheidereit C: The NF-κB/Rel and IκB gene families: mediators of immune response and inflammation. J Mol Med 1996;74:749-769.
6. Baeuerle PA, Henkel T: Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994;12:141-179.
7. Miyamoto S, Verma IM: Rel/NF-Kκ/IκB story. Adv Cancer Res 1995;66:255-292.
8. Schmitz ML, Baeuerle PA: Multi-step activation of NF-κB/Rel transcriptional factors. Immunobiology 1995;193:116-127.
9. Liou HC, Sha WC, Scott ML, Baltimore D: Sequential induction of NF-κB/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994;14:5349-5359.
10. Matthews JR, Hay RT: Regulation of the DNA binding activity of NF-κB. Int J Biochem Cell Biol 1995;27:865-879.
11. Akira S, Kishimoto T: NF-IL6 and NF-κB in cytokine gene regulation. Adv Immunol 1997;65:1-46.
12. Schreck R, Rieber P, Baeuerle P: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J 1991;10:2247-2258.
13. Baeuerle PA, Baltimore D: NF-κB: ten years after. Cell 1996; 87:13-20.
14. Janosch P, Schellerer M, Seitz T, Reim P, Eulitz M, Brielmeier M, et al: Characterization of IκB kinases: IκBα is not phosphorylated by Raf-1 or protein kinase C isoenzymes, but is a casein kinase II substrate. J Biol Chem 1996;271:13868-13874.
15. Chiao PJ, Miyamoto S, Verma IM: Autoregulation of IκBα activity. Proc Natl Acad Sci U S A 1994;91:28-32.
16. Kopp EB, Ghosh S: NF-κB and Rel proteins in innate immunity. Adv Immunol 1995;58:1-17.
17. Beg A, Sha W, Bronson R, Ghosh S, Baltimore D: Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 1995;376:167-170.
18. Sharma HW, Narayanan R: The NF-κB transcription factor in oncogenesis. Anticancer Res 1996;16:589-596.
19. Griffin GE, Leung K, Folks TM, Kunkel S, Nabel GJ: Activation of HIV gene expression during monocyte differentiation by induction of NF-κB. Nature 1989;339:70-73.
20. Baeuerle PA, Baichwal VR: NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997;65:111-137.
21. Los M, Schenk H, Hexel K, Baeuerle PA, Dorge W, Schulze-Osthoff K: IL-2 gene expression and NF-κB activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J 1995;14:3731-3740.
22. Jain J, Loh C, Rao A: Transcriptional regulation of the IL-2 gene. Curr Opin Immunol 1995;7:333-342.
23. Köntgen F, Grumont R, Strasser A, Metcalf D, Li R, Gerondakis S: Mice lacking the c-Rel protooncogene exhibit defects in lymphocyte proliferation, humoral immunity, and IL-2 expression. Genes Dev 1995;9:1965-1977.
24. Chen CC, Manning AM: Transcriptional regulation of endothelial cell adhesion molecules: a dominant role for NF-κB. Agents Actions 1995;47:135-141.
25. Segars JH, Nagata T, Bours V, Medin JA, Franzoso G, Blanco JCG, et al: Retinoic acid induction of major compatibility complex class I genes in NTera-2 embryonal carcinoma cells involves induction of NF-κB (p50-p65) and retinoic acid receptor-β-retinoid X receptor-β heterodimers. Mol Cell Biol 1993;13:6157-6169.
26. Hemar A, Cereghini S, Cornet V, Israel A, Greene W, Dautry-Varsat A: κB binding proteins are constitutively expressed in an IL-2 autocrine human T cell line. J Immunol 1991;146:2409-2416.
27. Sha W, Liou HC, Tuomanen E, Baltimore D: Targeted disruption of the p50 subunit of NF-κB leads multifocal defects in immune responses. Cell 1995;80:321-330.
28. Bach FH, Ferran C, Soares M, Wrighton CJ, Anrather J, Winkler H, et al: Modification of vascular responses in xenotransplantation: inflammation and apoptosis. Nature Med 1997;3:944-948.
29. Bach FH, Ferran C, Candinas D, Miyatake T, Koyamada N, Mark W, et al: Accommodation of xenografts: expression of protective genes in endothelial and smooth muscle cells. Transplant Proc 1997;29:56-58.
30. Handel ML, McMorrow LB, Gravallese EM: Nuclear factor-κB in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 1995;38:1762-1770.
31. Sakurada S, Kato T, Okamoto T: Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int Immunol 1996;8:1483-1493.
32. Roshak AK, Jackson JR, McGough K, Chabot-Fletcher M, Mochan E, Marshall LA: Manipulation of distinct NF-κB proteins alters interleukin-1β-induced human rheumatoid synovial fibroblast prostaglandin E2 formation. J Biol Chem 1996;271:31496-31501.
33. Barnes PJ: Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996;154:S21-S27.
34. Stacey MA, Sun G, Vassalli G, Marini M, Bellini A, Mattoli S: The allergen Der pi induces NF-κB activation through interference with IκBα function in asthmatic bronchial epithelial cells. Biochem Biophys Res Commun 1997;236:522-526.
35. 2 integrin in vivo. J Leukoc Biol 1996;59:145-151.
36. Böhrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Bottiger BW, et al: Role of NF-κB in the mortality of sepsis. J Clin Invest 1997;100:972-985.
37. Neurath MF, Pettersson S, Meyer zum Buschenfelde, Strober W: Local administration of antisense phosphorothiotate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nature Med 1996;2:998-1004.
38. Schwartz MD, Moore EE, Moore FA, Shenkar R, Moine P, Haenel JB, Abraham E: Nuclear factor-κB is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 1996;24:1285-1292.
39. Brand K, Page S, Rogler G, Bartsch A, Brandi R, Knuechel R, et al: Activated transcription factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996;97:1715-1722.
40. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kalscnmidt C: Transcription factor NF-κB is activated in primary neurons by amyloid β-peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sd U S A 1997;94:2642-2647.
41. Ray A, Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription of NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci U S A 1994; 91:752-756.
42. Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T, Matsushima K: Novel mechanism of glucocorticoid-mediated gene repression: nuclear factor-κB is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem 1994; 269:13289-13295.
43. Caldenhoven E, Liden J, Wissink, Van de Stolpr A, Raaijmakers J, Koenderman L, et al: Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 1995;9: 401-412.
44. Auphan N, DiDinato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995;270:286-290.
45. Kleinert H, Euchenhofer C, Ihrig-Biedert I, Forstermann U: Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-κB. Mol Pharmacol 1996;49:15-21.
46. Brostjan C, Anrather J, Csizmadia V, Natarajan G, Winkler H: Glucocorticoids inhibit E-selectin expression by targetting NF-κB and not ATF/c-Jun. J Immunol 1997;158:3836-3844.
47. Cato AC, Wade E: Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays 1996;18:371-378.
48. Tsao PW, Suzuki T, Totsuka R, Murata T, Takagi T, Ohmachi Y, et al: The effect of dexamethasone on the expression of activated NF-κB in adjuvant arthritis. Clin Immunol Immunopathol 1997;83:173-178.
49. Crofford LJ, Wilder RL, Ristimaki AP, Remmers EF, Epps HR, Hla T: Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1β, phorbol ester, and corticosteroids. J Clin Invest 1994;93:1095-1101.
50. Crofford LJ, Tan B, McCarthy CJ, Hla T: Involvement of nuclear factor κB in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum 1997;40:226-236.
51. Didonato JA, Saatcioglu F, Karin M: Molecular mechanisms of immunosuppression and anti-inflammatory activities by glucocorticoids. Am J Respir Crit Care Med 1996;154:S11-S15.
52. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS: Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-286.
53. Brostjan C, Anrather J, Csizmadia V, Stroka D, Scares M, Bach FH, Winkler H: Glucocorticoid mediated repression of NF-κB activity in endothelial cells does not involve induction of IκB synthesis. J Biol Chem 1996;171:19612-19616.
54. Adcock IM, Brown CR, Barnes PJ: Tumor necrosis factor α causes retention of activated glucocorticoid receptor within the cytoplasm of A549 cells. Biochem Biophys Res Commun 1996; 225:545-550.
55. Schreiber SL, Crabtree GR: The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-142.
56. Franz B, Nordby EC, Bren G, Steffan N, Paya CV, Kinkade RL, et al: Calcineurin acts in synergy with PMA to inactivate IκB/ MAD3, an inhibitor of NF-κB. EMBO J 1994;13:861-870.
57. McCaffrey PG, Kim PK, Valge-Archer VE, Sen R, Rao A: Cyclosporin A sensitivity of the NF-κB site of the IL2Rα promoter in untransformed murine T cells. Nucl Acids Res 1994;22:2134-2142.
58. Wechsler AS, Gordon MC, Dendorfer U, LeClair KP: Induction of IL-8 expression in T cells uses the CD28 costimulatory pathway. J Immunol 1994;153:2515-2523.
59. Okamoto S, Mukaida N, Yasumoto K, Rice N, Ishikawa Y, Horiguchi H, et al: The interleukin-8 AP-1 and κB-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization. J Biol Chem 1994;269:8582-8589.
60. Venkataraman L, Burakoff SJ, Sen R: FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. J Exp Med 1995;181:1091-1099.
61. Kunz D, Walker G, Eberhardt W, Nitsch D, Pfeilschifter J: Interleukin 1β-induced expression of nitric oxide synthase in rat renal mesangial cells is suppressed by cyclosporin A. Biochem Biophys Res Commun 1995;216:438-446.
62. Cockerill GW, Bert AG, Ryan GR, Gamble JR, Vadas MA, Cockerill PN: Regulation of granulocyte-macrophage colony-stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT. Blood 1995;86:2689-2698.
63. Holschermann H, Durfeld F, Maus U, Bierhaus A, Heidinger K, Lohmeyer J, et al: Cyclosporin A inhibits tissue expression in monocytes/macrophages. Blood 1996;88:3837-3845.
64. Meyer S, Kohler NG, Joly A: Cyclosporin A is an uncompetitive inhibitor of proteosome activity and prevents NF-κB activation. FEBS Lett 1997;413:354-358.
65. Marienfeld R, Neumann M, Chuvpilo S, Escher C, Kneitz B, Avots A, et al: Cyclosporin A interferes with the inducible degradation of NF-κB inhibitors, but not with the processing of p105/ NF-κB1 in T cells. Eur J Immunol 1997;27:1601-1609.
66. Nadler SG, Eversole ACB, Tepper MA, Cleaveland JS: Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Ther Drug Monit 1995;17:700-703.
67. Ramos EL, Nadler SG, Grasela DM, Kelly SL: Deoxyspergualin: mechanism of action and pharmacokinetics. Transplant Proc 1996;28:873-875.
68. Tepper MA, Nadler SG, Esselstyn J, Sterbenz KG: Deoxyspergualin inhibits light chain expression in 70Z/3 pre-B cells by blocking LPS-induced NF-κB activation. J Immunol 1995;155: 2427-2436.
69. Melnick J, Argon Y: Molecular chaperons and the biosynthesis of antigen receptors. Immunol Today 1995;16:243-250.
70. Weissmann G: The actions of NSAIDs. Hosp Pract 1991;26: 60-76.
71. Mitchell JA, Akarasereenont P, Thiemmermann C, Flower RJ, Vane JR: Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993;90:11693-11697.
72. Kopp E, Ghosh S: Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994;265:956-959.
73. Pierce JW, Read MA, Ding H, Luscinskas, Collins T: Salicylates inhibit IκBα phosphorylation, endothelial leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol 1996;156:3961-3969.
74. Weber C, Erl W, Pietsch A, Weber PC: Aspirin inhibits nuclear factor-κB mobilization and monocyte adhesion in stimulated human endothelial cells. Curculation 1995;91:1914-1917.
75. Vervoordeldonk MJ, Torra IM, Aarsman AJ, van den Bosch H: Aspirin inhibits expression of the interleukin-1β-inducible group II phospholipase A2. FEBS Lett 1996;397:108-112.
76. Fung-Leung W, Pope B, Chourmouzis E, Panakos JA, Lau CY: Tepoxalin, a novel immunomodulatory compound, synergizes with CsA in suppression of graft-versus-host reaction and allogeneic skin graft rejection. Transplantation 1995;60:362-368.
77. Kazmi SMI, Plante RK, Visconti V, Taylor GR, Zhou L, Lau CY: Suppression of NF-κB activation and NF-κB-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. J Cell Biochem 1995;57:299-310.
78. Ritchie DM, Argentieri DC, Aparicio BL, Plante RK, Lau CY, Barbone AG: Cytokine modulating-activity of tepoxalin, a new potential antirheumatic. Int J Immunopharmacol 1995;17:805-812.
79. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Mantiatis T, Collins T: The proteosome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995;2:493-506.
80. Wang P, Wu P, Siegel M, Egan R, Billah M: Interleukin-10 inhibits nuclear NF-κB activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995;270:9558-9563.
81. May MJ, Ghosh S: Signal transduction through NF-κB. Immunol Today 1998;19:80-88.